A carregar...
ATLANTIS: a Phase III study of lurbinectedin/doxorubicin versus topotecan or cyclophosphamide/doxorubicin/vincristine in patients with small-cell lung cancer who have failed one prior platinum-containing line
Lurbinectedin is an inhibitor of active transcription of protein-coding genes, causing DNA-break accumulation, apoptosis and modulation of the tumor microenvironment. Early-phase clinical trials indicate promising activity of lurbinectedin in small-cell lung cancer. Here, we describe the rationale a...
Na minha lista:
| Publicado no: | Future Oncol |
|---|---|
| Main Authors: | , , , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
Future Medicine Ltd
2019
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6331752/ https://ncbi.nlm.nih.gov/pubmed/30362375 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2217/fon-2018-0597 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|